SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.